PALLAS AFT-05

Breast Cancer

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Key Team Members

Principal Investigator

Steven A. Madden, MD

Research Coordinator

Katherine "Kate" Madden

Not Accepting Patients

Check if You’re Eligible

(803) 935-8300

Research@lexhealth.org

About the Trial

The purpose of this study is to compare any good and bad effects of using 2 years of Palbociclib in combination with standard anti-hormone therapy to using standard antihormone therapy alone and to evaluate the likelihood that invasive breast cancer returns.